Insight into the mechanism of laquinimod action - Journal of the Neurological Sciences
Swedish Biotech Faces Another Phase III Flop in Multiple Sclerosis
Meet the Compound: Laquinimod – HD Insights
Is Teva doomed after Copaxone's increased competition and Laquinimod's failed Phase III trial? - Pharmaceutical Technology
Teva launches personalised digital support for MS patients - PMLiVE
Teva finally dumps laquinimod, ending failure-riddled saga | Fierce Biotech
Teva drops development of laquinimod - PharmaTimes
Laquinimod | C19H17ClN2O3 - PubChem
MS Therapy Laquinimod Fails to Meet Key Trial Goal of Slowing the Disease
Advances in Oral Drugs for Multiple Sclerosis | Erase MS
Laquinimod - Wikipedia
Laquinimod dampens hyperactive cytokine production in Huntington's disease patient myeloid cells - Dobson - 2016 - Journal of Neurochemistry - Wiley Online Library
After Multiple Failures, Teva Returns Laquinimod Rights to Active Biotech | BioSpace
Teva and Active Biotech Expand Investigational MS Treatment Program
First patient enrolled in Phase II study evaluating laquinimod
Teva's Respiratory Drugs Contribute 11% to Specialty Medicines
Teva Announce the Completion of Enrollment in Laquinimod Phase III Clinical Trial | Technology Networks
Multiple Sclerosis Research: Will Teva and Biogen Come together for the sake of DMF, laquinimod polypill
Laquinimod, an Oral Product in Development for the Treatment of Relapsing Remitting Multiple Sclerosis Steve Glenski, PharmD Medical Affairs Teva Neuroscience. - ppt download
TREATMENT WITH GLATIRAMER ACETATE DELAYS CONVERSION TO CLINICALLY DEFINITE MULTIPLE SCLEROSIS (CDMS) IN PATIENTS WITH CLINICALLY
Teva and Active Biotech Announce Expansion of Laquinimod Clinical Development Program with New Trial in Primary Progressive Multiple Sclerosis and First Patient Screened in Huntington's Disease Trial
Laquinimod, an Oral Product in Development for the Treatment of Relapsing Remitting Multiple Sclerosis Steve Glenski, PharmD Medical Affairs Teva Neuroscience. - ppt download
Laquinimod, an Oral Product in Development for the Treatment of Relapsing Remitting Multiple Sclerosis Steve Glenski, PharmD Medical Affairs Teva Neuroscience. - ppt download
Teva gets patent for invention related to multiple sclerosis drug | Business Standard News
Laquinimod, an Oral Product in Development for the Treatment of Relapsing Remitting Multiple Sclerosis Steve Glenski, PharmD Medical Affairs Teva Neuroscience. - ppt download
